A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer.
Yasushi Sato
No relevant relationships to disclose
Hiroyuki Ohnuma
No relevant relationships to disclose
Masahiro Hirakawa
No relevant relationships to disclose
Minoru Takahashi
No relevant relationships to disclose
Takahiro Osuga
No relevant relationships to disclose
Kohichi Takada
No relevant relationships to disclose
Tsuyoshi Hayashi
No relevant relationships to disclose
Tsutomu Sato
No relevant relationships to disclose
Koji Miyanishi
No relevant relationships to disclose
Rishu Takimoto
No relevant relationships to disclose
Masayoshi Kobune
No relevant relationships to disclose
Kenji Okita
No relevant relationships to disclose
Tomohisa Furuhata
No relevant relationships to disclose
Koichi Hirata
No relevant relationships to disclose
Junji Kato
No relevant relationships to disclose